Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/3/2017
SIETES contiene 91704 citas

 
 
 1 a 20 de 3185 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
3. Cita con resumen
Anónimo. Selexipag (Uptravi) for pulmonary arterial hypertension. Med Lett Drugs Ther 2016;58:21-3. [Ref.ID 100680]
4.Tiene citas relacionadas Cita con resumen
O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016;388:761-75. [Ref.ID 100609]
5.Tiene citas relacionadas Cita con resumen
Anónimo. Atrial fibrillation and stroke: unrecognised and undertreated. Lancet 2016;388:731. [Ref.ID 100608]
6. Cita con resumen
Whittle J. Blood pressure variability and cardiovascular risk. BMJ 2016;354:i4190. [Ref.ID 100604]
7. Cita con resumen
Stevens SL, Wood S, Koshiaris C, Law K, Glasziou P, Stevens RJ, McManus RJ. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ 2016;354:i4098. [Ref.ID 100603]
8. Cita con resumen
Mente A, O’Donnell M, Rangarajan S, Dagenais G, Lear S, McQueen M, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Li W, Lu Y, Yi S, Rensheng L, Iqbal R, Mony P, Yusuf R, Yusoff K, Szuba A, Oguz A, Rosengren A, Bahonar A, Yusufali A, Schutte AE, Chifamba J, Mann JFE, Anand SS, Teo K, Yusuf S, for the PURE EPIDREAM and ONTARGET/TRANSCEND Investigators. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet 2016;388:465-85. [Ref.ID 100513]
9. Cita con resumen
O'Brien E. Salt—too much or too little?. Lancet 2016;388:439-40. [Ref.ID 100512]
10.Tiene citas relacionadas Cita con resumen
Cunningham CJ. Research into “real world” older patients is needed. BMJ 2016;353:i3136. [Ref.ID 100379]
11.Tiene citas relacionadas Cita con resumen
Messerli FH, Bangalore S, Grossman E. Adverse effects and tolerability of ß blockers. BMJ 2016;353:i3142. [Ref.ID 100378]
12. Cita con resumen
Jackson JW. The cardiovascular safety of methylphenidate. BMJ 2016;353:i2874. [Ref.ID 100356]
14. Cita con resumen
Alpern JD, Song J, Stauffer WM. Essential medicines in the United States - Why access is diminishing. N Engl J Med 2016;374:1904-7. [Ref.ID 100324]
15. Cita con resumen
Rouse B, Cipriani A, Shi Q, Coleman AL, Dickersin K, Li T. Network meta-analysis for clinical practice guidelines: a case study, on first-line medical therapies for primary open-angle glaucoma. Ann Intern Med 2016;164:674-82. [Ref.ID 100297]
16. Cita con resumen
Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B. Cardiovascular and renal outcomes of renin–angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLOS Medicine 2016:8 de marzo. [Ref.ID 100213]
18. Cita con resumen
Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, McMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahími K, Perkovic V, Rodgers A. Effect of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-43. [Ref.ID 100094]
20.Tiene citas relacionadas Cita con resumen
Majumdar SR. Antihypertensive treatments for adults with type 2 diabetes. BMJ 2016;352:i560. [Ref.ID 100052]
Seleccionar todas
 
 1 a 20 de 3185 siguiente >>